Azenta Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Azenta şirketinin toplam hissedar öz sermayesi $1.8B ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $2.1B ve $331.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$462.09m
Eşitlik	US$1.77b
Toplam yükümlülükler	US$331.07m
Toplam varlıklar	US$2.10b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

Nov 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AZTA 'nin kısa vadeli varlıkları ( $832.8M ) kısa vadeli yükümlülüklerini ( $204.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: AZTA şirketinin kısa vadeli varlıkları ( $832.8M ) uzun vadeli yükümlülüklerini ( $126.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AZTA borçsuzdur.

Borcun Azaltılması: AZTA şirketinin 5 yıl önce borç/öz sermaye oranı 4.5% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan AZTA mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: AZTA kârlı değildir ancak serbest nakit akışı pozitif olsa ve yılda 34.9 % oranında azalsa bile 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Azenta Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Independent Director recently bought US$495k worth of stock

Consensus revenue estimates decrease by 14%

Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%

Price target decreased by 7.2% to US$56.60

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Full year 2024 earnings: EPS misses analyst expectations

Azenta, Inc. Announces Chief Financial Officer Changes

Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024

Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Azenta: Life Science Play Is Not Coming To Life

Azenta, Inc. Announces Management Changes

Price target decreased by 7.2% to US$58.25

Consensus EPS estimates fall by 29%

Forecast to breakeven in 2026

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024

Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024

Stephen Schwartz to Retire as CEO of Azenta, Inc

Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024

Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?

Now 20% overvalued

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Consensus EPS estimates fall by 20%

New major risk - Revenue and earnings growth

Senior VP notifies of intention to sell stock

Consensus EPS estimates fall by 19%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Azenta, Inc. Announces the Launch of the BioArc Ultra

Price target increased by 9.9% to US$72.00

Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Key Executive notifies of intention to sell stock

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 20%

Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023

Is There An Opportunity With Azenta, Inc.'s (NASDAQ:AZTA) 31% Undervaluation?

Politan Capital Provides Information to the Shareholders

Consensus EPS estimates upgraded to US$0.39 loss

Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023

Politan Capital Management Engages in Discussions with Azenta

Politan Capital Management Engages in Discussions with Azenta

At US$50.66, Is It Time To Put Azenta, Inc. (NASDAQ:AZTA) On Your Watch List?

Now 23% undervalued

New minor risk - Insider selling

Insider recently sold US$407k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023

Estimating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Consensus EPS estimates upgraded to US$0.49 loss

Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023

Now 20% undervalued

Independent Chairman notifies of intention to sell stock

Is Azenta, Inc. (NASDAQ:AZTA) Potentially Undervalued?

Price target decreased by 13% to US$52.50

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 11%

Revenue Downgrade: Here's What Analysts Forecast For Azenta, Inc. (NASDAQ:AZTA)

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023

Is Azenta, Inc. (NASDAQ:AZTA) Worth US$42.5 Based On Its Intrinsic Value?

Consensus EPS estimates fall by 48%

Price target decreased by 8.2% to US$64.60

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023